A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge. / Christensen, Louise Westberg Strejby; Iversen, Esben; Andersen, Aino Leegaard; Walls, Anne Byriel; Rasmussen, Line Jee Hartmann; Andersen, Ove; Kallemose, Thomas; Houlind, Morten Baltzer.
In: Basic and Clinical Pharmacology and Toxicology, Vol. 135, No. 3, 2024, p. 364-371.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge
AU - Christensen, Louise Westberg Strejby
AU - Iversen, Esben
AU - Andersen, Aino Leegaard
AU - Walls, Anne Byriel
AU - Rasmussen, Line Jee Hartmann
AU - Andersen, Ove
AU - Kallemose, Thomas
AU - Houlind, Morten Baltzer
N1 - Publisher Copyright: © 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
PY - 2024
Y1 - 2024
N2 - Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic chronic inflammation. Elevated suPAR levels are associated with adverse clinical outcomes, but a small subset of patients with low suPAR also experience poor outcomes. Therefore, we aimed to characterize patients presenting to the emergency department with low suPAR (<3 ng/mL) who died within 90 days after discharge in a registry-based study. Compared to patients with low suPAR who survived (n = 15 122), those who died within 90 days (n = 87) had higher age (75.4 years), higher medication use (7.0; 71.3% with polypharmacy) and more blood tests outside reference intervals (5.0) (including C-reactive protein, neutrophils and albumin), and the most common diagnoses were chronic pulmonary disease (27.6%), cerebrovascular disease (18.4%) and dementia (11.5%). Patients with low suPAR were more morbid than what was reflected by suPAR alone. Future studies must determine which factors that contribute the most to potential algorithms when stratifying patients based on their risk of adverse clinical outcomes. These data indicate that inclusion of medication data could be relevant.
AB - Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic chronic inflammation. Elevated suPAR levels are associated with adverse clinical outcomes, but a small subset of patients with low suPAR also experience poor outcomes. Therefore, we aimed to characterize patients presenting to the emergency department with low suPAR (<3 ng/mL) who died within 90 days after discharge in a registry-based study. Compared to patients with low suPAR who survived (n = 15 122), those who died within 90 days (n = 87) had higher age (75.4 years), higher medication use (7.0; 71.3% with polypharmacy) and more blood tests outside reference intervals (5.0) (including C-reactive protein, neutrophils and albumin), and the most common diagnoses were chronic pulmonary disease (27.6%), cerebrovascular disease (18.4%) and dementia (11.5%). Patients with low suPAR were more morbid than what was reflected by suPAR alone. Future studies must determine which factors that contribute the most to potential algorithms when stratifying patients based on their risk of adverse clinical outcomes. These data indicate that inclusion of medication data could be relevant.
KW - adverse clinical outcomes
KW - medication review
KW - mortality
KW - polypharmacy
KW - risk stratification
KW - suPAR
U2 - 10.1111/bcpt.14050
DO - 10.1111/bcpt.14050
M3 - Journal article
C2 - 38988231
AN - SCOPUS:85198085548
VL - 135
SP - 364
EP - 371
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
SN - 1742-7835
IS - 3
ER -
ID: 399160046